3 results
Approved WMORecruiting
To increase the major pathological response rate (< 10% vital tumor cells) to neoadjuvant treatment by integrating both trastuzumab and pertuzumab into perioperative chemotherapy for HER-2 positive, resectable gastric cancer.
Approved WMOCompleted
In this study, we to confirm the cuff design and make sure it works. Aspects such as safety and ease of use are also evaluated.
Approved WMOCompleted
To demonstrate the benefit of maintenance treatment with avelumab plus BSC vs. BSC alone in prolonging overall survival (OS) in patients with unresectable locally advanced or metastatic UC whose disease did not progress on or following completion of…